Capmatinib (Tabrecta) is a targeted therapy for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation, offering a new treatment option for patients with this specific genetic mutation.

What Are the Purchase Channels for Capmatinib (Tabrecta)?

Overseas Purchase

(1) Patients can choose to consult and purchase the drug at hospital pharmacies or licensed pharmacies in countries or regions where capmatinib has been approved for marketing.

(2) Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase through Medical Service Institutions

(1) Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

(2) These institutions can usually provide legal import channels, as well as professional consultation and guidance.

Precautions for the Purchase and Use of Capmatinib (Tabrecta)

Strictly Follow Medical Evaluation

(1) Mutation Verification: Before medication, the mutation must be confirmed through an FDA-approved test to avoid ineffective treatment.

(2) Contraindication Screening: Although there are no absolute contraindications, potential risks such as liver and kidney function and underlying cardiopulmonary diseases need to be evaluated.

Drug Information Verification

Packaging Labeling: The genuine capmatinib drug box should contain the following information: the brand name "TABRECTA", the active ingredient "capmatinib", specifications (150mg/200mg), batch number and expiration date.

Tablet Characteristics(1) The 150mg tablet is a gray-orange oval film-coated tablet with beveled edges without scratches, marked with "DU" on one side and "NVR" on the other.

(2) The 200mg tablet is a yellow oval film-coated tablet with beveled edges without scratches, marked with "LO" on one side and "NVR" on the other.

Storage and Transportation Conditions

(1) The drug should be sealed and stored at 20°C-25°C, and the desiccant in the original packaging must not be discarded.

(2) Any unused portion should be discarded 6 weeks after opening.

Drug Interactions

(1) Avoid concurrent use with strong or moderate CYP3A inducers (such as rifampicin), as this may lead to decreased blood drug concentration and affect efficacy.

(2) Capmatinib may increase the exposure of drugs that are substrates of CYP1A2, P-gp, and BCRP. Dose adjustments are required under the guidance of a doctor when used in combination.

Authenticity Identification of Capmatinib (Tabrecta)

Official Traceability System

Check the drug batch number through Novartis official website or FDA drug database, and verify the version of the package insert.

Physical Characteristic Verification

Genuine tablets have no signs of fragmentation, uniform surface coating, and clear, non-abrasive markings.

Adverse Reaction Monitoring

(1) Common adverse reactions of genuine capmatinib include peripheral edema (59%), nausea (46%), musculoskeletal pain (40%), and fatigue (34%).

(2) If no typical reactions occur after use, counterfeit drugs should be suspected.